New White Paper: Seven Steps for Allogeneic Cell Therapy Success
Center for Breakthrough Medicines
In the new white paper, CBM experts, explore the latest strategies and technologies for allogeneic cell therapy success.
Allogeneic, or “donor-derived”, CAR T cells have the potential to broaden access to treatment for patients. To prepare for commercial scale, companies must think through a number of considerations around scale-up, aseptic processing, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.
Allogeneic, or “donor-derived”, CAR T cells have the potential to broaden access to treatment for patients. To prepare for commercial scale, companies must think through a number of considerations around scale-up, aseptic processing, aseptic processing, single-use systems, facility design, starting material, supply chain, and logistics.
In need of immediate assistance for your product development? Simply call to speak with a CBM expert: 866-274-4009.